Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MMP3 | P08254 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17087400 | 0.94 | KDM4E (0.46) | KDM4EGAAGLASMN1; SMN2ALDH1A1 | |
| SCHEMBL17518388 | 0.87 | L3MBTL1 (0.46) | L3MBTL1SMN1; SMN2ALDH1A1TSHRMAPT | |
| SCHEMBL17518390 | 0.86 | GAA (0.48) | KDM4EGAAGLASMN1; SMN2ALDH1A1 | |
| SCHEMBL17518309 | 0.86 | L3MBTL1 (0.49) | L3MBTL1SMN1; SMN2ALDH1A1TSHRMAPT | |
| SCHEMBL17518331 | 0.85 | GAA (0.47) | KDM4EGAAGLASMN1; SMN2ALDH1A1 | |
| SCHEMBL17518251 | 0.84 | GAA (0.46) | KDM4EGAAGLASMN1; SMN2ALDH1A1 | |
| SCHEMBL17524667 | 0.81 | SIGMAR1 (0.40) | L3MBTL1SMN1; SMN2PAOX | |
| SCHEMBL17087480 | 0.80 | PAOX (0.37) | GAAL3MBTL1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL17518316 | 0.77 | KMT2A (0.35) | KDM4EL3MBTL1SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL17518363 | 0.77 | DPP4 (0.33) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266927-B2 | Cyclosporin A analogs | ALLERGAN, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20160039880-A1 | CYCLOSPORIN A ANALOGS | ALLERGAN, INC. | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039880-A1 | CYCLOSPORIN A ANALOGS | TSLP, CHP1, PPP3R1 | KDM4E 4374/4885GAA 1994/4885GLA 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.